A team led by University of Minnesota Twin Cities engineering researchers analyzed the fundamental properties and structures of lung surfactant—a naturally occurring substance that helps human and animal lungs expand and contract—providing insight that could eventually help scientists develop better treatments for respiratory illnesses.
The paper is published in Science Advances, a peer-reviewed, multidisciplinary scientific journal published by the American Association for the Advancement of Science.
Both human and animal lungs naturally produce a surfactant, a substance consisting of lipids and proteins that coats the lungs and decreases the surface tension as we inhale and exhale, making it easier to breathe.
Respiratory illnesses like pneumonia or COVID-19 can impede the lung surfactant from working properly, leading to complications in breathing. A similar issue occurs in pre-term babies, who sometimes haven’t yet developed the ability to produce the substance and suffer from Neonatal Respiratory Distress Syndrome. Right now, treatments consist of giving humans replacement surfactant taken from animal lungs, but researchers have been working to create synthetic surfactants to treat these conditions for years.